Search Results

Semler Scientific, Inc. reported financial results for the first quarter ended March 31, 2024.

Semler Scientific, Inc. today announced that it will report financial results for the first quarter ended March 31, 2024, after the close of U.S. financial market.

Semler Scientific, Inc., a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, reported financial results for the fourth quarter and full year ended December 31, 2023.

Semler Scientific, Inc. today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023, after the close on Tuesday, March 5, 2024.

- Semler Scientific, Inc. announced that Eric Semler and William H.C. Chang, who collectively beneficially own more than 20% of Semler Scientific’s outstanding shares, will immediately join Semler Scientific’s board of directors as new independent directors.

Semler Scientific, Inc., a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, announced Renae Cormier, CFO, will participate in the following investor conference.

Semler Scientific, Inc. announced that it is set to join the Russell 2000® and 3000® Indexes at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens on June 26, 2023.

Semler Scientific, Inc., a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, reported financial results for the three and six months ended June 30, 2023.

Semler Scientific, Inc. today announced the appointment of a chief financial officer (CFO), record quarterly revenues expected for the second quarter of 2023 and a strategic streamlining.

Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today announced that it will report financial results for the third quarter and first nine months ended September 30, 2023, after the close of U.S. financial markets on Thursday, November 9, 2023.